Fabino Enterprises Ltd
Incorporated in 2011, Fabino Enterprises manufactures, markets, trades, and does packing of pharmaceutical and other wellness focused consumer products[1]
- Market Cap ₹ 2.75 Cr.
- Current Price ₹ 13.1
- High / Low ₹ 39.0 / 13.0
- Stock P/E
- Book Value ₹ 19.2
- Dividend Yield 0.00 %
- ROCE 7.16 %
- ROE 3.08 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.68 times its book value
- Debtor days have improved from 277 to 177 days.
- Company's working capital requirements have reduced from 277 days to 103 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 1.52% over last 3 years.
- Company has high debtors of 177 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| 2.76 | 7.52 | 3.06 | 4.19 | 3.36 | 6.01 | 18.00 | 14.46 | |
| 2.44 | 7.20 | 2.99 | 4.09 | 3.33 | 5.90 | 17.83 | 14.59 | |
| Operating Profit | 0.32 | 0.32 | 0.07 | 0.10 | 0.03 | 0.11 | 0.17 | -0.13 |
| OPM % | 11.59% | 4.26% | 2.29% | 2.39% | 0.89% | 1.83% | 0.94% | -0.90% |
| 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.29 | 0.33 | |
| Interest | 0.29 | 0.20 | 0.01 | 0.01 | 0.01 | 0.02 | 0.13 | 0.15 |
| Depreciation | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.07 | 0.09 |
| Profit before tax | 0.00 | 0.10 | 0.04 | 0.07 | 0.01 | 0.06 | 0.26 | -0.04 |
| Tax % | 30.00% | 25.00% | 28.57% | 0.00% | 16.67% | 50.00% | ||
| 0.00 | 0.07 | 0.03 | 0.05 | 0.01 | 0.05 | 0.13 | -0.16 | |
| EPS in Rs | 0.00 | 4.67 | 0.25 | 0.24 | 0.05 | 0.24 | 0.62 | -0.76 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 63% |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 38% |
| TTM: | -420% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -25% |
| 1 Year: | -55% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 3% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.15 | 0.15 | 1.20 | 2.10 | 2.10 | 2.10 | 2.10 | 2.10 |
| Reserves | 0.45 | 0.52 | 0.10 | 2.00 | 2.01 | 2.06 | 2.19 | 1.94 |
| 2.52 | 1.08 | 0.31 | 0.05 | 0.41 | 0.84 | 1.61 | 1.64 | |
| 5.43 | 1.83 | 0.65 | 0.48 | 0.50 | 4.50 | 7.11 | 4.00 | |
| Total Liabilities | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.01 | 9.68 |
| 0.10 | 0.08 | 0.16 | 0.17 | 0.15 | 0.24 | 0.46 | 0.42 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 0.05 |
| 8.45 | 3.50 | 2.10 | 4.46 | 4.87 | 9.21 | 12.50 | 9.21 | |
| Total Assets | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.01 | 9.68 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| 0.18 | 2.44 | -0.45 | -1.90 | -0.68 | -2.99 | -0.12 | |
| -0.01 | 0.00 | -0.10 | -0.05 | -0.01 | -0.18 | 2.11 | |
| -0.18 | -2.37 | 0.45 | 2.47 | 0.34 | 0.43 | 0.73 | |
| Net Cash Flow | 0.00 | 0.07 | -0.10 | 0.52 | -0.35 | -2.75 | 2.72 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 338.55 | 113.09 | 158.64 | 125.44 | 274.84 | 377.75 | 177.43 |
| Inventory Days | 988.71 | 15.36 | 62.61 | 174.83 | 147.24 | 88.59 | 26.56 |
| Days Payable | 1,024.81 | 77.34 | 63.94 | 34.76 | 45.78 | 294.40 | 152.06 |
| Cash Conversion Cycle | 302.45 | 51.11 | 157.31 | 265.51 | 376.29 | 171.94 | 51.93 |
| Working Capital Days | 19.84 | 51.93 | 165.80 | 292.70 | 444.30 | 282.40 | 103.21 |
| ROCE % | 12.32% | 2.98% | 2.78% | 0.46% | 1.68% | 7.16% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
14 Jan - Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025
-
Announcement under Regulation 30 (LODR)-Resignation of Director
26 Dec 2025 - Kuldeep Solanki resigned as Non-Executive Independent Director effective December 26, 2025; succession at upcoming board meeting.
-
Announcement under Regulation 30 (LODR)-Change in Management
26 Dec 2025 - Appointed Deepali Singla (DIN 11442242) as Additional Independent Director, effective December 26, 2025, subject to shareholders' approval.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, December 26, 2025
26 Dec 2025 - Resignation of Kuldeep Solanki; appointment of Deepali Singla as Independent Director effective Dec 26, 2025.
-
Results- Financial Results For The Half Year Ended September 30, 2025
13 Nov 2025 - Unaudited H1 results to Sep 30, 2025: Consolidated revenue Rs690.90L; consolidated loss Rs18.59L; standalone loss Rs24.87L
Business Overview:[1][2]
a) FEL is an ISO 9001:2015 pharmaceutical company located near the Delhi NCR region. It offers a wide range of allopathic and herbal products.
b) Company markets pharmaceutical formulation for domestic market and sells through own distribution network and sales force under
their own brand name
c) It gets Ayurvedic formulations manufactured through Loan Licensing facilities, Packing, Labelling etc.
d) Company exports wellness and FMCG products like Coffee, Malt powder, Protein powder, Hair shampoo which it also markets